- Home
- NVS
NVS
Novartis AG
as 05-20-2024 12:33pm EST
$.
+$.
+.%
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 210.6B | IPO Year: | 1991 |
| Target Price: | $115.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | 3.68% | Dividend Payout Frequency: | Annual |
| EPS: | 7.38 | EPS Growth: | 127.08 |
| 52 Week Low/High: | $92.19 - $108.78 | Next Earning Date: | 07-16-2024 |
| Revenue: | $49,924,000,000 | Revenue Growth: | 8.81% |
| Revenue Growth (this year): | 5.2% | Revenue Growth (next year): | 4.02% |
Share on Social Networks:
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
BioPharma Dive
3 days ago
Erasca restructures; Novartis moves to complete MorphoSys deal
GlobeNewswire
4 days ago
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
GlobeNewswire
5 days ago
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Motley Fool
6 days ago
3 Magnificent Stocks That Are Passive Income Machines
Thomson Reuters StreetEvents
7 days ago
Q1 2024 Legend Biotech Corp Earnings Call
GlobeNewswire
13 days ago
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Motley Fool
15 days ago
2 Magnificent Dividend Stocks to Hold for the Next Decade
Zacks
17 days ago